Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Tolaney, Sara
Item TypeName
Academic Article Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
Concept Chemotherapy, Adjuvant
Academic Article A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Academic Article Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
Academic Article Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Academic Article Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Academic Article Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.
Academic Article The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.
Academic Article Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Academic Article Randomized trial of a physical activity intervention in women with metastatic breast cancer.
Academic Article Optimal Management of Early and Advanced HER2 Breast Cancer.
Academic Article De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
Academic Article Optimal treatment of early stage HER2-positive breast cancer.
Academic Article The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Academic Article Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Academic Article Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Academic Article A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
Academic Article Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Academic Article Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Search Criteria
  • Chemotherapy Adjuvant
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.